Bluesail Medical

What Bluesail Medical does

Bluesail Medical Co., Ltd. (蓝帆医疗股份有限公司; SZSE: 002382) is a publicly listed China-headquartered medical device platform founded in 2003, headquartered in Zibo, Shandong Province, with operations across 130+ countries and 8,000+ employees globally. The company operates four integrated business units: Cardio and Neuro Vascular (coronary drug-eluting stents, drug-coated balloons, TAVR systems, intravascular lithotripsy/coronary shockwave catheters, and peripheral vascular devices); Minimally Invasive Surgery (electric laparoscopic staplers, ultrasonic scalpels, and endoscopic instruments); Healthcare Protective (PVC, nitrile, latex, TPE, and polyurethane disposable gloves, plus face masks); and First Aid Healthcare (first aid kits, AED devices meeting DIN/BS/ANSI standards). Underlying technology is anchored by proprietary BA9 (Biolimus A9) anti-proliferative drug chemistry, the BioFreedom polymer-free drug-coated stent platform (the first globally approved for high bleeding risk patients), and a triangle R&D support system across China, Singapore (via Biosensors subsidiary acquired in 2018), and Germany (via NVT subsidiary acquired 2019-2020).

The business model combines hardware sales across B2B medical device channels and B2B/B2C protective product channels. Medical device pricing in China is largely determined through participation in national volume-based procurement (集采) programs, while international sales operate through direct subsidiary networks and distributors in 130+ countries. The protective products segment leverages 500 billion+ unit annual glove production capacity (22% global PVC glove market share, #2 China nitrile export position) for OEM and own-brand distribution. Revenue streams span direct hospital sales (2,300+ China hospitals, 8,000+ globally), national procurement contracts (first-place coronary stent bid in 2020 procurement), international OEM exports, and consumer retail through pharmacy/e-commerce channels.

The company is positioned as a platform player with diversified business mix balancing high-value interventional devices against high-volume protective products. Capital structure includes significant strategic investor participation following 2024 financings (1 billion CNY for cardio subsidiary, USD 200M from Thai partner HKG for health protection). Manufacturing footprint spans Weihai Industrial Park, Ningbo, Changzhou, and Zibo; R&D centers in Shanghai, Singapore, and Germany; commercial offices in Beijing, Shanghai, New Hampshire (USA), and Singapore. Recent strategic emphasis is on AI integration in cardiology (Ruixin partnership), structural heart expansion (TAVR via ALLEGRA), and international regulatory approvals (CE MDR, FDA, PMDA, MDSAP certifications across multiple product lines).

Name

Bluesail Medical

Legal name

Bluesail Medical Co., Ltd. (蓝帆医疗股份有限公司)

Website

https://bluesail.cn

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Bluesail Medical (蓝帆医疗) is a China-based, publicly listed medical device platform operating across four business units—cardiovascular interventions, minimally invasive surgery, healthcare protective products, and first aid supplies—serving hospitals in 130+ countries.

Ownership category

akta.pro rank

Product category

Medical Devices & Healthcare Protective Products

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM)

akta.pro secondary industries

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care) (CRADAMAB)

Keywords

• Interventional cardiology devices
• Cardiovascular medical devices
• Disposable protective gloves
• Minimally invasive surgical instruments
• First aid emergency products

Headquarters

HQ city

Linzi

HQ country

China

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. High-value Medical Devices: Coronary stents, drug-coated balloons, TAVR systems, IVL systems, surgical instruments for cardio/neurovascular and minimally invasive surgery segments
2. Healthcare Protective Products: PVC gloves, nitrile gloves, TPE gloves, latex gloves, face masks, polyurethane gloves
3. First Aid Healthcare Products: First aid kits, emergency supplies,急救包 products for automotive, industrial, military applications
4. OEM/Export Manufacturing: Export of protective products to international markets including North America, South America, Europe and Asia

Pricing tiers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Core offering

Bluesail Medical manufactures and sells four integrated lines of medical and healthcare products: (1) Cardio and Neuro Vascular devices including coronary drug-eluting stents (EXCEL, BioFreedom), BA9 drug-coated balloons, ALLEGRA TAVR systems, and IVL shockwave catheters for hospitals worldwide; (2) Minimally Invasive Surgery instruments including powered endoscopic staplers and ultrasonic energy devices; (3) Healthcare Protective products such as PVC, nitrile, latex, TPE and polyurethane disposable gloves and face masks; and (4) First Aid products including vehicle and household first-aid kits and AED devices. The company runs dedicated R&D and manufacturing in China, Singapore and Germany.

Product overview

蓝帆医疗是一家以中国为核心、面向全球的跨国医疗器械平台型企业，构建了「高值+低值」模式互补的多元化业务布局。旗下分为四个事业部：1）心脑血管事业部涵盖冠脉介入、结构性心脏病、神经介入及外周介入四条赛道，产品包括BioFreedom®药物涂层支架、柏腾™ BA9 DCB药物球囊、ALLEGRA® TAVR系统、SoniCracker™冲击波球囊等；2）微创外科事业部提供星晖™/星曜™电动腔镜吻合器、TisFree®超声刀、RenoVue®镜头清洗器等外科器械；3）健康防护事业部生产一次性手套（PVC、丁腈、乳胶、聚氨酯）和口罩等防护产品；4）应急救护事业部提供急救包、AED等急救产品。蓝帆医疗实现了从简单到复杂PCI病变整体解决方案的「一站式」供应，产品覆盖全球130多个国家和地区。

Differentiator

Problem solved

Functional benefit

Brands

• BioFreedom: Polymer-free drug-coated stent system - the world's first clinically validated stent specifically for high bleeding risk (HBR) patients, written into European cardiovascular treatment guidelines
• BA9 DCB / 柏腾
• ALLEGRA TAVR System
• SoniCracker
• Blue Sail Surgical (蓝帆外科)
• 蓝帆护理 (Bluesail Care)

Products and services

• BioFreedom® Polymer-Free Drug-Coated Stent Polymer-free drug-coated stent designed specifically for high bleeding risk (HBR) patients; first stent globally approved for HBR indication by NMPA, FDA, CE and PMDA, and the only stent in the world written into European cardiovascular treatment guidelines for HBR patients.
• Boteng™ BA9 DCB Drug-Coated Balloon China's first approved sirolimus-class drug-coated balloon using proprietary BA9 (Biolimus A9) drug technology; fills the gap of sirolimus and its derivatives in the drug-coated balloon field.
• ALLEGRA® Transcatheter Aortic Valve System (TAVR) Third-generation transcatheter aortic valve replacement system with short stent frame design providing maximum effective orifice area (EOA); approved in over 45 countries and regions globally.
• SoniCracker™ Intravascular Lithotripsy (IVL) System IVL shockwave catheter system for treating calcified coronary lesions with 18 specification models including 15mm and 2.0mm smallest diameter options; the most complete specification set of IVL catheters in China.
• Lithonic™ Intravascular Lithotripsy System Coronary intravascular lithotripsy system from Singapore-based Biosensors subsidiary, CE-certified; same-platform technology as SoniCracker with complementary specification set.
• Star Bright / Star Rapid (星晛/星晷) Powered Endoscopic Staplers Next-generation intelligent powered endoscopic staplers independently designed by Bluesail Surgical (蓝帆外科); China's first approved intelligent powered endoscopic staplers with intelligent chip enabling single-hand operation.
• TisFree® Ultrasonic Soft Tissue Cutting & Hemostasis Device Ultrasonic energy device for soft tissue cutting and hemostasis in surgical procedures; complements the MIS business unit's energy sealing and dissecting portfolio.
• RenoVue® Single-Use Closed-Endoscopic Lens Cleaner Original Bluesail Surgical single-use endoscopic lens cleaner that can quickly and effectively clean contaminated scopes during surgery, avoiding surgical interruption.
• Disposable Glove Product Line (PVC, Nitrile, Latex, TPE, Polyurethane) Comprehensive disposable glove portfolio covering PVC, nitrile, latex, polyurethane and TPE chemistries; Bluesail is one of only a few companies globally offering all four major health protection glove categories, with 500 billion+ unit production capacity.
• Disposable Face Mask Product Line Disposable protective face masks for medical, industrial and consumer applications; part of the Healthcare Protective business unit.
• First Aid Kit Product Line (Vehicle, Office, Industrial) First-aid kits, emergency supplies, and AED devices meeting international certifications including German DIN, British BS and American ANSI standards; for vehicles, office, industrial and household emergency use.
• Xinjianding™ Non-compliant Peripheral Super High Pressure Balloon (千斤顶) Non-compliant peripheral super high pressure balloon using patented braided balloon structure with rated burst pressure of 40 atm; for peripheral vascular intervention.
• Xinmai™ Coronary Cutting Balloon Dilation Catheter (心脉) Coronary cutting balloon dilation catheter that uses a specially designed cutting surface to concentrate local stress during low-pressure dilation, effectively expanding lesions.
• Xinghen™ Coronary Orbital Atherectomy Balloon Dilation Catheter (星痕) Coronary orbital atherectomy balloon dilation catheter; the only product with helical triple-wire orbital atherectomy achieving 360° high-efficiency focused pressure dilation, RBP up to 20 atm.
• BioMC™ Coronary Microcatheter Coronary microcatheter developed and manufactured by Bluesail Medical's Cardio & Neurovascular BU through its Singapore-based Biosensors International Group; CE certified.
• ALLEGRA Plus TAVR Delivery System Third-generation TAVR delivery system building on ALLEGRA, with optimized delivery and valve design including bovine pericardium with unique V-shaped sealing skirt that reduces paravalvular leak by 30%.
• IMPERIA™ Retrievable TAVR Delivery System Next-generation retrievable delivery system used with ALLEGRA, allowing the physician to perform valve retrieval and repositioning during the procedure.

Quantifiable outcome

• One heart patient treated every 30 seconds globally with Bluesail stents
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Ruixin Medical (睿心医疗)coreTechnology or Integration · 17 May 2026Strategic partnership to integrate AI technology with coronary functional assessment. Bluesail's products combined with Ruixin's AI capabilities for enhanced cardiac care solutions.
• Wuyou Pulse (无忧跳动)coreStrategic or Co-development Partner · 22 April 2026Strategic cooperation on PFO degradable occluder products. Expands Bluesail's structural heart disease product portfolio.
• Juzheng Medical (矩正医疗)coreChannel Partner/ Reseller/ Distributor · 22 April 2026Agency partnership for ICAS (Intracranial Artery Stenosis) technology to fill domestic technology gaps and create a win-win ecosystem.
• Wanhua Chemical (万华化学)coreStrategic or Co-development Partner · 14 April 2026Strategic cooperation on polyurethane materials research and application. Five-year joint development resulted in successful polyurethane glove technology breakthrough in 2024. The partnership provides Bluesail with access to innovative materials and helps reduce US tariff impact.
• Wofim Medical (沃福曼)coreChannel Partner/ Reseller/ Distributor · 31 March 2026Exclusive agency partnership for OCT (Optical Coherence Tomography) products in Asia Pacific region. Also upgrading domestic cooperation to a new level.
• Guangdong Kaili Emergency Supply Chain (凯利应急供应链)minorStrategic or Co-development Partner · 19 December 2023Joint donation of protective supplies to Gansu earthquake disaster area. Kaili is a national emergency industry demonstration base creator.
• Sinopharm Medical (国药器械)coreStrategic or Co-development Partner · 28 November 2023Strategic cooperation covering product supply and sales, medical industry cooperation, and investment/financing collaboration. Bluesail leverages Sinopharm's nationwide logistics network and distribution channels to strengthen supply chain capabilities in China's hospital market.
• Chinese Red Cross Society (中国红十字会)minorStrategic or Co-development PartnerJoint donations to Turkey and Syria earthquake relief efforts. Long-term partnership in disaster relief and emergency response.
• China National Healthcare Security Administration (国家医保局)coreChannel Partner/ Reseller/ DistributorParticipation in national volume-based procurement (集中带量采购) for coronary stents. First place winner in 2020 national procurement, providing products to national healthcare system.
• China Construction Eighth Engineering Bureau (中建八局)minorImplementation/ SI/ Consulting PartnerStrategic cooperation for Shanghai Global Innovation Headquarters construction project. Eight Bureau serves as general contractor for the project.

Scale indicators22 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Boston Scientific: Major global interventional cardiology competitor with overlapping drug-eluting stent and drug-coated balloon products. Sets clinical evidence standards that Bluesail's BioFreedom and BA9 DCB must match to win premium hospital accounts outside China.
• Abbott Vascular: Global market leader in coronary stents, drug-coated balloons, and structural heart intervention. Competes with Bluesail's BioFreedom, BA9 DCB, and ALLEGRA products across international markets and sets pricing benchmarks for premium-tier accounts.
• Edwards Lifesciences: Global TAVR market leader and the primary competitive benchmark for Bluesail's ALLEGRA transcatheter aortic valve system. Comparable in structural heart focus, regulatory positioning, and physician training infrastructure.
• Shandong Weigao Group: Large Chinese medical device and consumables manufacturer based in Shandong (same province as Bluesail) with overlapping orthopedic, surgical consumable, and interventional product lines. Broader portfolio than Bluesail but competes for hospital channel and procurement access.

Direct peers

• Lepu Medical: Chinese cardiovascular medical device company with comparable coronary stent and interventional cardiology portfolio, including drug-eluting stents and balloons. Direct domestic competitor sharing the same national volume-based procurement dynamic and overlapping hospital relationships in China.
• MicroPort Scientific: Shanghai-based cardiovascular device maker offering overlapping coronary intervention and structural heart products. Comparable in scale, business model, regulatory strategy, and Chinese market positioning; competes directly for hospital procurement contracts.
• Shockwave Medical: US-based pioneer and global market leader in intravascular lithotripsy (IVL) for calcified coronary and peripheral lesions. The direct technology and clinical comparator for Bluesail's SoniCracker and Lithonic IVL systems across international markets.
• Hartalega Holdings: Malaysian-based global leader in nitrile examination gloves with comparable production capacity and customer base. Direct competitor in the high-volume disposable glove market where Bluesail claims Top 2 China export share.
• Top Glove Corporation: World's largest rubber glove manufacturer and the primary global competitor in PVC and nitrile medical gloves. Directly comparable to Bluesail's Healthcare Protective business unit in capacity, end-market exposure, and pricing dynamics.

Others

• Mindray Medical:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks2 records

Key highlights7 records

Customer concentration

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries10 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bluesail Medical